111 related articles for article (PubMed ID: 25505588)
1. Discrepancies in listed adverse drug reactions in pharmaceutical product information supplied by the regulatory authorities in Denmark and the USA.
Eriksson R; Aagaard L; Jensen LJ; Borisova L; Hørlück D; Brunak S; Hansen EH
Pharmacol Res Perspect; 2014 Jun; 2(3):e00038. PubMed ID: 25505588
[TBL] [Abstract][Full Text] [Related]
2. Adverse drug reaction labelling for atomoxetine, methylphenidate and modafinil: comparison of product information for oral formulations in Australia, Denmark and the United States.
Aagaard L; Hansen EH
Curr Drug Saf; 2013 Jul; 8(3):162-8. PubMed ID: 23914751
[TBL] [Abstract][Full Text] [Related]
3. Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents.
Cornelius VR; Liu K; Peacock J; Sauzet O
BMJ Open; 2016 Mar; 6(3):e010599. PubMed ID: 26996819
[TBL] [Abstract][Full Text] [Related]
4. Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA.
Wu L; Ingle T; Liu Z; Zhao-Wong A; Harris S; Thakkar S; Zhou G; Yang J; Xu J; Mehta D; Ge W; Tong W; Fang H
BMC Bioinformatics; 2019 Mar; 20(Suppl 2):97. PubMed ID: 30871458
[TBL] [Abstract][Full Text] [Related]
5. Information on adverse drug reactions-Proof of principle for a structured database that allows customization of drug information.
Kusch MKP; Zien A; Hachenberg C; Haefeli WE; Seidling HM
Int J Med Inform; 2020 Jan; 133():103970. PubMed ID: 31704490
[TBL] [Abstract][Full Text] [Related]
6. Comparison of pregnancy and lactation labeling for attention-deficit hyperactivity disorder drugs marketed in Australia, the USA, Denmark, and the UK.
Warrer P; Aagaard L; Hansen EH
Drug Saf; 2014 Oct; 37(10):805-13. PubMed ID: 25112669
[TBL] [Abstract][Full Text] [Related]
7. Language does not come "in boxes": Assessing discrepancies between adverse drug reactions spontaneous reporting and MedDRA® codes in European Portuguese.
Inácio P; Airaksinen M; Cavaco A
Res Social Adm Pharm; 2015; 11(5):664-74. PubMed ID: 25596069
[TBL] [Abstract][Full Text] [Related]
8. Monitoring drug safety in Astrakhan, Russia.
Kirilochev OO; Dorfman IP; Umerova AR
Int J Risk Saf Med; 2015; 27 Suppl 1():S33-4. PubMed ID: 26639700
[TBL] [Abstract][Full Text] [Related]
9. Food and Drug Administration monitoring of adverse drug reactions.
Sills JM; Tanner LA; Milstien JB
Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
[TBL] [Abstract][Full Text] [Related]
10. A dataset of 200 structured product labels annotated for adverse drug reactions.
Demner-Fushman D; Shooshan SE; Rodriguez L; Aronson AR; Lang F; Rogers W; Roberts K; Tonning J
Sci Data; 2018 Jan; 5():180001. PubMed ID: 29381145
[TBL] [Abstract][Full Text] [Related]
11. Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs.
Kesselheim AS; Franklin JM; Avorn J; Duke JD
BMJ Qual Saf; 2013 Sep; 22(9):727-34. PubMed ID: 23620531
[TBL] [Abstract][Full Text] [Related]
12. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project.
Ladewski LA; Belknap SM; Nebeker JR; Sartor O; Lyons EA; Kuzel TC; Tallman MS; Raisch DW; Auerbach AR; Schumock GT; Kwaan HC; Bennett CL
J Clin Oncol; 2003 Oct; 21(20):3859-66. PubMed ID: 14551305
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
14. Provision of information on regulatory authorities' websites.
Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
[TBL] [Abstract][Full Text] [Related]
15. Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK).
Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
Eur J Clin Pharmacol; 2005 Aug; 61(7):531-6. PubMed ID: 16041596
[TBL] [Abstract][Full Text] [Related]
16. Paediatric adverse drug reaction reporting: understanding and future directions.
Carleton BC; Smith MA; Gelin MN; Heathcote SC
Can J Clin Pharmacol; 2007; 14(1):e45-57. PubMed ID: 17297195
[TBL] [Abstract][Full Text] [Related]
17. Safety learning from drugs of the same class: room for improvement.
Stefansdottir G; Knol MJ; Arnardottir AH; van der Elst ME; Grobbee DE; Leufkens HG; De Bruin ML
Clin Pharmacol Ther; 2012 May; 91(5):872-80. PubMed ID: 22453192
[TBL] [Abstract][Full Text] [Related]
18. Adverse drug reactions of psycopharmacs.
Skvrce NM; Arapović S; Krnić D; Sarinić VM; Zezelić S; Bagatin K; Leventić J; Tomić S
Psychiatr Danub; 2010 Sep; 22(3):441-5. PubMed ID: 20856189
[TBL] [Abstract][Full Text] [Related]
19. Consistency in the safety labeling of bioequivalent medications.
Duke J; Friedlin J; Li X
Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):294-301. PubMed ID: 23042584
[TBL] [Abstract][Full Text] [Related]
20. A Qualitative and Quantitative Comparison of Adverse Drug Reaction Data in Different Drug Information Sources.
Randhawa GK; Sharma R; Singh NR; Sharma N
Int J Appl Basic Med Res; 2017; 7(4):223-227. PubMed ID: 29308358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
